JP6835846B2 - ブルトン型チロシンキナーゼの阻害剤としての多環式化合物 - Google Patents

ブルトン型チロシンキナーゼの阻害剤としての多環式化合物 Download PDF

Info

Publication number
JP6835846B2
JP6835846B2 JP2018530000A JP2018530000A JP6835846B2 JP 6835846 B2 JP6835846 B2 JP 6835846B2 JP 2018530000 A JP2018530000 A JP 2018530000A JP 2018530000 A JP2018530000 A JP 2018530000A JP 6835846 B2 JP6835846 B2 JP 6835846B2
Authority
JP
Japan
Prior art keywords
oxo
dihydro
carboxamide
thia
triazaacenaftylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018530000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536686A5 (enExample
JP2018536686A (ja
Inventor
アローラ，ニドヒ
エム． バカニー，ジェネシィス
エム． バカニー，ジェネシィス
バーベイ，ジョセフ，ケント
ディー． ベンベネック，スコット
ディー． ベンベネック，スコット
ツァイ，ミン
チェン，ウェイ
プーリー デクハット，シャーロット
プーリー デクハット，シャーロット
ピー． エドワーズ，ジェームス
ピー． エドワーズ，ジェームス
ゴッシュ，ブラーマナンダ
クルーター，ケヴィン
リー，ガン
エス． ティケナー，マーク
エス． ティケナー，マーク
ディー． ベナブル，ジェニファー
ディー． ベナブル，ジェニファー
ウェイ，ジエンメイ
ジェイ．エム． ウィーナー，ジョン
ジェイ．エム． ウィーナー，ジョン
ウー，ヤオ
シャオ，クン
ザン，フェイフアン
ジュ，ヤオピン
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2018536686A publication Critical patent/JP2018536686A/ja
Publication of JP2018536686A5 publication Critical patent/JP2018536686A5/ja
Application granted granted Critical
Publication of JP6835846B2 publication Critical patent/JP6835846B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018530000A 2015-12-10 2016-12-09 ブルトン型チロシンキナーゼの阻害剤としての多環式化合物 Active JP6835846B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10
US62/265,836 2015-12-10
PCT/US2016/065954 WO2017100662A1 (en) 2015-12-10 2016-12-09 Polycyclic compounds as inhibitors of bruton's tyrosine kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021016602A Division JP7072690B2 (ja) 2015-12-10 2021-02-04 ブルトン型チロシンキナーゼの阻害剤としての多環式化合物

Publications (3)

Publication Number Publication Date
JP2018536686A JP2018536686A (ja) 2018-12-13
JP2018536686A5 JP2018536686A5 (enExample) 2019-11-07
JP6835846B2 true JP6835846B2 (ja) 2021-02-24

Family

ID=57681784

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018530000A Active JP6835846B2 (ja) 2015-12-10 2016-12-09 ブルトン型チロシンキナーゼの阻害剤としての多環式化合物
JP2021016602A Active JP7072690B2 (ja) 2015-12-10 2021-02-04 ブルトン型チロシンキナーゼの阻害剤としての多環式化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021016602A Active JP7072690B2 (ja) 2015-12-10 2021-02-04 ブルトン型チロシンキナーゼの阻害剤としての多環式化合物

Country Status (30)

Country Link
US (5) US10717745B2 (enExample)
EP (2) EP3386991B1 (enExample)
JP (2) JP6835846B2 (enExample)
KR (1) KR102103395B1 (enExample)
CN (2) CN108884106A (enExample)
AR (1) AR107042A1 (enExample)
AU (1) AU2016366541B2 (enExample)
BR (1) BR112018011526B1 (enExample)
CA (1) CA3007990C (enExample)
CY (1) CY1123263T1 (enExample)
DK (1) DK3386991T3 (enExample)
EA (1) EA035168B1 (enExample)
ES (1) ES2805835T3 (enExample)
HR (1) HRP20201193T1 (enExample)
HU (1) HUE049502T2 (enExample)
IL (1) IL259863B (enExample)
JO (1) JO3794B1 (enExample)
LT (1) LT3386991T (enExample)
MA (2) MA43409B1 (enExample)
MD (1) MD3386991T2 (enExample)
ME (1) ME03803B (enExample)
MX (1) MX387590B (enExample)
PL (1) PL3386991T3 (enExample)
PT (1) PT3386991T (enExample)
RS (1) RS60604B1 (enExample)
SI (1) SI3386991T1 (enExample)
SM (1) SMT202000404T1 (enExample)
TW (1) TWI729047B (enExample)
UY (1) UY37015A (enExample)
WO (1) WO2017100662A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022141851A (ja) * 2015-12-10 2022-09-29 ヤンセン ファーマシューティカ エヌ．ベー． ブルトン型チロシンキナーゼの阻害剤及びその使用方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
WO2018170220A1 (en) * 2017-03-15 2018-09-20 Janssen Sciences Ireland Uc Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
EP4089095A4 (en) * 2020-01-07 2024-03-27 Medshine Discovery Inc. DEUTERATED THIENOPYRIDINE COMPOUND
EP4301365A1 (en) * 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
MX2023014435A (es) 2021-06-04 2024-03-08 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
MX2023015147A (es) * 2021-06-30 2024-04-01 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
WO2023016995A1 (en) 2021-08-09 2023-02-16 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
MX2024010134A (es) * 2022-02-18 2024-08-27 Janssen Pharmaceutica Nv Sintesis de inhibidores de tirosina quinasa de bruton.
WO2025262118A1 (en) 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
AU2005284796A1 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
US7427625B2 (en) * 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2010056875A1 (en) * 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
EP2471789B9 (en) * 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
EP2970291B1 (en) 2013-03-15 2022-05-11 Janssen Pharmaceutica, N.V. Processes and intermediates for preparing a medicament
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022141851A (ja) * 2015-12-10 2022-09-29 ヤンセン ファーマシューティカ エヌ．ベー． ブルトン型チロシンキナーゼの阻害剤及びその使用方法
JP7471348B2 (ja) 2015-12-10 2024-04-19 ヤンセン ファーマシューティカ エヌ．ベー． ブルトン型チロシンキナーゼの阻害剤及びその使用方法

Also Published As

Publication number Publication date
SMT202000404T1 (it) 2020-09-10
BR112018011526B1 (pt) 2024-02-27
NZ742484A (en) 2021-09-24
CA3007990C (en) 2024-01-02
KR20180093974A (ko) 2018-08-22
US20190276471A1 (en) 2019-09-12
CN113121562B (zh) 2022-09-13
EP3719022B1 (en) 2026-07-08
CN108884106A (zh) 2018-11-23
IL259863A (en) 2018-07-31
US20230097422A1 (en) 2023-03-30
BR112018011526A2 (pt) 2018-11-21
EA035168B1 (ru) 2020-05-08
AU2016366541B2 (en) 2021-05-13
LT3386991T (lt) 2020-08-25
RS60604B1 (sr) 2020-08-31
PL3386991T3 (pl) 2021-03-08
SI3386991T1 (sl) 2020-08-31
TW201734021A (zh) 2017-10-01
CA3007990A1 (en) 2017-06-15
PT3386991T (pt) 2020-08-18
JO3794B1 (ar) 2021-01-31
HUE049502T2 (hu) 2020-09-28
TWI729047B (zh) 2021-06-01
EA201891378A1 (ru) 2018-12-28
JP2021073286A (ja) 2021-05-13
IL259863B (en) 2020-06-30
UY37015A (es) 2017-06-30
ME03803B (me) 2021-04-20
WO2017100662A1 (en) 2017-06-15
CN113121562A (zh) 2021-07-16
KR102103395B1 (ko) 2020-04-23
MX387590B (es) 2025-03-18
AR107042A1 (es) 2018-03-14
US20210101910A1 (en) 2021-04-08
EP3719022A1 (en) 2020-10-07
MA43409B1 (fr) 2020-10-28
JP7072690B2 (ja) 2022-05-20
EP3386991A1 (en) 2018-10-17
US20240383914A1 (en) 2024-11-21
US11319329B2 (en) 2022-05-03
HRP20201193T1 (hr) 2020-11-13
ES2805835T3 (es) 2021-02-15
US12065446B2 (en) 2024-08-20
US20170283430A1 (en) 2017-10-05
DK3386991T3 (da) 2020-07-13
CY1123263T1 (el) 2021-12-31
US10934310B2 (en) 2021-03-02
JP2018536686A (ja) 2018-12-13
AU2016366541A1 (en) 2018-05-31
MX2018007075A (es) 2018-11-09
EP3386991B1 (en) 2020-06-03
MD3386991T2 (ro) 2020-11-30
US10717745B2 (en) 2020-07-21
MA53110A (fr) 2021-05-12

Similar Documents

Publication Publication Date Title
JP7072690B2 (ja) ブルトン型チロシンキナーゼの阻害剤としての多環式化合物
AU2016366546B2 (en) Inhibitors of Bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103058A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
HK40052204B (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK40052204A (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK40038735A (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
NZ742484B2 (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK1262330A1 (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK1262330B (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210204

R150 Certificate of patent or registration of utility model

Ref document number: 6835846

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250